A synthetic antibody fragment is engineered, capable of binding to human claudin-4, providing insights into its structure and selective binding mechanism, possibly enabling precise modulation of tight junctions in tissue-specific therapeutic interventions.
- Satchal K. Erramilli
- Pawel K. Dominik
- Alex J. Vecchio